Satellite Symposia
Satellite Symposia (SS) are independent educational events held during the Crohn’s & Colitis Congress® and are intended to complement the official scientific program. They offer a unique opportunity to present content before or after Congress sessions and may provide CME/CE credit.The top areas of interest for attendees are Clinical, Research, and Microbiome in Gastrointestinal and Liver Diseases.
Time Slots & Fees
Thursday, January 22, 2026
Two Evening time slots (concurrent)
- Fee: $30,000
- Restrictions: May not begin before 6:00 p.m., including registration and F&B service.
- Room Capacity (with round dining tables and A/V set up): 110
Friday, January 23, 2026
Two Morning time slots (concurrent)
- Fee: $30,000
- Restrictions: Must conclude by 7:30 a.m., including any Q&A
- Room Capacity (with round dining tables and A/V set up): 110
One Lunch time slot
- Fee: $40,000
- Restrictions: Must be held between 11:30 a.m. – 2:00 p.m., including registration, F&B service, and Q&A.
- Room Capacity (with round dining tables and A/V set up): 140
As more information for the Satellite Symposia becomes available this page will be updated. Last updated, September 2025.
Satellite Symposia Schedule
Satellite Symposia Schedule
Thank you for registering for the 2025 Crohn’s & Colitis Congress®. While you’re at the Congress, you can take advantage of any of the following satellite symposia. Please be sure to register for each one separately.
Thursday, February 6, 2025
IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Faculty
- Corey A. Siegel, MD, MS (Moderator)
- Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE, FCCF
- Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN
- Uma Mahadevan, MD
In this CME Outfitters symposium, expert faculty will instruct learners on the role of pro-inflammatory cytokines in the pathogenesis of IBD. Learners will be guided on the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis and how to appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD. Faculty will model the development of individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent.
Here Come the IL-23p19 Inhibitors: Exploring New Treatments in IBD
In partnership with Lilly, USA.
Join expert faculty, Prof. Vipul Jairath and Dr. Aline Charabaty, as they explore the new and evolving treatment landscape in inflammatory bowel disease (IBD) during interactive, patient case-based discussions.
Learning Objectives:
- Examine the evolving treatment goals in the management of IBD
- Interpret the efficacy and safety, including the long-term data for IL-23p19 inhibitors
- Apply these concepts in case discussions
Faculty
- Prof. Vipul Jairath
- Dr. Aline Charabat
Friday, February 7, 2025
Updates in TNF-alpa inhibitors for Inflammatory Bowel Disease and new modes of delivery for patient centered care
In partnership with Celltrion USA Medical Affairs.
Faculty
- Jessica R. Allegretti, MD, MPH, FACG, AGAF
Despite advances in IBD treatments, TNF alpha inhibitors remain the mainstay in patient care. Subcutaneous Infliximab offers an alternative method of delivery and simplifies patient care. This session will discuss one- and two-year clinical data for Infliximab-dyyb SC injection, as well as the importance of steady, stable serum drug levels in the patient treatment journey.
Arm in Arm With Crohn’s Disease Experts: A Master Class in Noninvasive Imaging and Histologic Endpoints
Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Gastroenterological Association (AGA). This activity is supported by an educational grant from Lilly.
Faculty
- Jordan Axelrad, MD, MPH, FACG
- Russell D. Cohen, MD, FACG, AGAF
- Marla Dubinsky, MD
- Amy Stewart, MSN, FNP-C
- Ryan Ungaro, MD, MS
The goal of this activity is to improve knowledge, competence, and performance among GI HCP learners on treat-to-target strategies in CD, noninvasive imaging, and the newest treatment targets, including histological endpoints, to optimize and individualize patient care.
We look forward to working with you and ensuring that you have a positive experience sharing your innovations with our attendees.
Interested in learning more or have additional questions, please contact:
CHLOE STEIN
Senior Coordinator, Industry Sales and Operations
American Gastroenterological Association